Lexeo Therapeutics Management
Management criteria checks 0/4
Lexeo Therapeutics' CEO is R. Townsend, appointed in Jan 2020, has a tenure of 5.33 years. total yearly compensation is $4.38M, comprised of 13.7% salary and 86.3% bonuses, including company stock and options. directly owns 0.26% of the company’s shares, worth $277.62K. The average tenure of the management team and the board of directors is 1.3 years and 2.5 years respectively.
Key information
R. Townsend
Chief executive officer
US$4.4m
Total compensation
| CEO salary percentage | 13.71% |
| CEO tenure | 5.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 1.3yrs |
| Board average tenure | 2.5yrs |
Recent management updates
Recent updates
Is Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Deliver On Growth Plans?
Jan 20
We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Oct 11Lexeo: Higher Dosing LX2006 Could Ignite FA Cardiomyopathy Program Further
Jul 16We're Hopeful That Lexeo Therapeutics (NASDAQ:LXEO) Will Use Its Cash Wisely
Jun 18Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Apr 09Lexeo Therapeutics: Only Smallcap Gene Therapy For Alzheimer's
Jan 29CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2025 | n/a | n/a | -US$109m |
| Dec 31 2024 | US$4m | US$600k | -US$98m |
| Sep 30 2024 | n/a | n/a | -US$87m |
| Jun 30 2024 | n/a | n/a | -US$77m |
| Mar 31 2024 | n/a | n/a | -US$69m |
| Dec 31 2023 | US$2m | US$508k | -US$66m |
| Sep 30 2023 | n/a | n/a | -US$67m |
| Jun 30 2023 | n/a | n/a | -US$64m |
| Mar 31 2023 | n/a | n/a | -US$64m |
| Dec 31 2022 | US$705k | US$465k | -US$59m |
| Dec 31 2021 | US$3m | US$411k | -US$51m |
Compensation vs Market: R.'s total compensation ($USD4.38M) is above average for companies of similar size in the US market ($USD655.68K).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
CEO
R. Townsend (43 yo)
Mr. R. Nolan Townsend is Director of Arbor Biotechnologies, Inc. from November 2023. He is Chief Executive Officer & Director of Lexeo Therapeutics, Inc since January 2020 Before joining Lexeo, Mr. Townsen...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$4.38m | 0.26% $ 277.6k | |
| Chief Medical Officer & Head of Research | 1.3yrs | US$3.16m | 0.013% $ 14.1k | |
| Chief Technical Officer | 1yr | US$3.56m | 0.017% $ 18.5k | |
| Co-Founder | no data | no data | 4.03% $ 4.3m | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Legal Officer | 3.2yrs | US$1.30m | 0.029% $ 31.0k | |
| Vice President of Corporate Development | less than a year | no data | no data | |
| Chief Development Officer | 2.3yrs | no data | 0.025% $ 27.2k | |
| Senior Vice President of Development Operations | less than a year | no data | no data | |
| VP & Corporate Controller | 3.3yrs | no data | no data |
Experienced Management: LXEO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 5.3yrs | US$4.38m | 0.26% $ 277.6k | |
| Co-Founder | 2.5yrs | no data | 4.03% $ 4.3m | |
| Independent Director | 3.3yrs | US$728.03k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$730.05k | 0% $ 0 | |
| Independent Director | 3.5yrs | US$278.31k | 0.092% $ 99.2k | |
| Independent Chairman of the Board | 4.3yrs | US$299.78k | 0% $ 0 | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.5yrs | no data | no data |
Experienced Board: LXEO's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 10:21 |
| End of Day Share Price | 2025/05/19 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lexeo Therapeutics, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Mitchell Kapoor | H.C. Wainwright & Co. |